Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Revenio Group

11.04 EUR-2.99 %7.10, 17.29
14,637 following

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
-2.99 %
-15.92 %
+5.47 %
-30.76 %
-41.14 %
-44.49 %
-36.92 %
-75.49 %
+593.91 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
464.74M EUR
Turnover
925.38K EUR
P/E (adj.) (26e)
16.58
EV/EBIT (adj.) (26e)
18.73
P/B (26e)
1.95
EV/S (26e)
3.01
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
16.50 EUR
Updated
23.09.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 23.09.2026

Latest extensive report

Released: 21.01.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
“We used to have a very highly profitable company → well, now it’s a lot less profitable company Return on capital was high → well, now it’s a lot lower Wanted to buy one technology → bought all sorts of things The company was a niche player. There was focus and it was the best in...
9/29/2026, 3:10 PM
by Optis
28
I chuckled a bit when I received a letter in the mail from Revenio a while ago, with Toijala predictably spouting corporate fluff line after line. Well, it’s nice to get mail—a rarity these days. Another chuckle at the fact that I left that classic single share in my account just...
yesterday
by Latela
14
Kaupankäynti merkkareilla päättyy sitten tänään 6.10. Myykää pois, jos ette aio osallistua antiin.
yesterday
by MattiZ
13
There is an interesting situation with Revenio right now, as the old share costs more than the new one. If you had a lot of Revenio in your portfolio, you could sell the old and buy the new.
yesterday
by Sergio
8
Nyt meni merkitseminen läpi kun rahat tuli T+2 pv ajassa OSTin hoitotilille. Se ei siis riitä, että OSTilta myy osakkeita ja saa varat käytettäväksi seuraaviin osakeostoihin. Merkintäoikeuksien käyttäminen osakesäästötilillä vaatii saman T+2 ajan kuin rahan poisnostaminen OSTilta...
9/30/2026, 7:35 AM
by palse
7
Yesterday’s arbitrage of about €0.20/share melted away today. According to Nordnet’s broker statistics, all the big net buyers today were American banks. The sellers, on the other hand, are somewhat more familiar players. Previously, you could get broker statistics for all daily ...
9/29/2026, 2:09 PM
by Juurikki
5
Of course, you can subscribe to new issues with an equity savings account (OST), but you can’t buy subscription rights (merkkari) because you can only buy shares within an OST. Correct me if I’m wrong.
9/29/2026, 10:22 AM
by FanTom
5
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.11
2026

Interim report Q3'26

Regulatory press release07.10.2026, 15.15

Managers' Transactions - Riad Sherif

Revenio Group
Regulatory press release07.10.2026, 15.15

Managers' Transactions - Ari Isomäki

Revenio Group
Regulatory press release07.10.2026, 15.15

Managers' Transactions - Riad Sherif

Revenio Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release07.10.2026, 15.15

Managers' Transactions - Anat Loewenstein

Revenio Group
Regulatory press release06.10.2026, 10.00

Managers' Transactions - Caravelle Capital SAS

Revenio Group
Regulatory press release05.10.2026, 11.30

Managers' Transactions - Marc Abitbol Consulting Services Ltd.

Revenio Group
Regulatory press release05.10.2026, 11.30

Managers' Transactions - Marc Abitbol

Revenio Group
Regulatory press release01.10.2026, 12.00

Managers' Transactions - Nicklas Hansen

Revenio Group
Regulatory press release30.09.2026, 13.00

Managers' Transactions - Erkki Tala

Revenio Group
Regulatory press release30.09.2026, 13.00

Managers' Transactions - Erkki Tala

Revenio Group
Regulatory press release30.09.2026, 13.00

Managers' Transactions - Jouni Toijala

Revenio Group
Regulatory press release30.09.2026, 13.00

Managers' Transactions - Erkki Tala

Revenio Group
Regulatory press release30.09.2026, 09.30

Managers' Transactions - Ari Isomäki

Revenio Group
Regulatory press release30.09.2026, 09.30

Managers' Transactions - Arne Boye Nielsen

Revenio Group
Regulatory press release30.09.2026, 09.30

Managers' Transactions - Ari Isomäki

Revenio Group
Regulatory press release30.09.2026, 09.30

Managers' Transactions - Umberto Bargiggia

Revenio Group
Regulatory press release30.09.2026, 09.30

Managers' Transactions - Bill Östman

Revenio Group
Regulatory press release30.09.2026, 09.30

Managers' Transactions - Heli Lindfors

Revenio Group
Regulatory press release30.09.2026, 09.30

Managers' Transactions - Ari Isomäki

Revenio Group
Modelportefølje: Revenios vægt stiger i porteføljen som følge af fortegningsrettsemissionen
Research28.09.2026, 09.11 by
Juha Kinnunen, Atte Riikola, Rauli Juva

Modelportefølje: Revenios vægt stiger i porteføljen som følge af fortegningsrettsemissionen

Modelporteføljen udnytter alle sine tegningsretter i Revenio og har derudover købt 471 rettigheder, hvilket gør, at vi tegner i alt 756 nye aktier i selskabets fortegningsemission til en kurs på 6,19 EUR pr. aktie.

Revenio Group